[Bleomycin and skin neoplasms].
D000505:Alopecia / Q000139:chemically induced; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001772:Blood Cell Count; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003864:Depression, Chemical; D004357:Drug Synergism; D005528:Foot; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006225:Hand; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced; D007642:Keratosis / Q000139:chemically induced; D007958:Leukocyte Count; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009182:Mycosis Fungoides / Q000188:drug therapy*; D010859:Pigmentation Disorders / Q000139:chemically induced; D011239:Prednisolone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012594:Scleroderma, Localized / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000139:chemically induced; D014747:Vinblastine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D014747:Vinblastine; D011239:Prednisolone
Bléomycine et néoplasies cutanées.